Tonix Pharmaceuticals Holding (TNXP) Return on Sales (2022 - 2026)

Tonix Pharmaceuticals Holding's Return on Sales history runs 5 years deep, the most recent figure standing at 0.06% for Q1 2026.

• On a quarterly basis, Return on Sales rose 1.0% year-over-year to 0.06% in Q1 2026; TTM through Mar 2026 was 0.08%, a 5.0% increase from a year earlier, with the FY2025 full-year figure at 0.1%, up 10.0% from the prior year.
• Return on Sales grew to 0.06% in Q1 2026 per TNXP's latest filing, from 0.09% in the prior quarter.
• Across five years, Return on Sales topped out at 0.05% in Q2 2022 and bottomed at 0.36% in Q2 2024.
• The 5-year median for Return on Sales is 0.08% (2022), against an average of 0.1%.
• Across the five-year window, Return on Sales decreased 28 bps in 2024 and increased 22 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.08% in 2022, then gained by 12 bps to 0.07% in 2023, then fell by 23 bps to 0.09% in 2024, then advanced by 1 bps to 0.09% in 2025, then jumped by 32 bps to 0.06% in 2026.
• Per Business Quant, the three latest TNXP Return on Sales figures stand at 0.06% (Q1 2026), 0.09% (Q4 2025), and 0.1% (Q3 2025).